Tempest Therapeutics Ownership
| TPST Stock | USD 0.92 0.01 1.10% |
Shares in Circulation | First Issued 2011-09-30 | Previous Quarter 22.5 M | Current Value 25.8 M | Avarage Shares Outstanding 4.3 M | Quarterly Volatility 7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tempest |
Tempest Stock Ownership Analysis
About 23.0% of the company shares are owned by institutional investors. The book value of Tempest Therapeutics was at this time reported as 1.21. The company recorded a loss per share of 1.53. Tempest Therapeutics last dividend was issued on the 10th of December 2018. The entity had 1:15 split on the 28th of June 2021. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Tempest Therapeutics contact LLM JD at 415 798 8589 or learn more at https://www.tempesttx.com.Besides selling stocks to institutional investors, Tempest Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tempest Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tempest Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tempest Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Tempest Therapeutics are currently held by insiders. Unlike Tempest Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tempest Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tempest Therapeutics' insider trades
Tempest Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tempest Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tempest Therapeutics backward and forwards among themselves. Tempest Therapeutics' institutional investor refers to the entity that pools money to purchase Tempest Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Davenport & Company Llc | 2024-09-30 | 50 K | Bank Of America Corp | 2024-06-30 | 43.3 K | State Street Corp | 2024-06-30 | 41.5 K | Empower Advisory Group Llc | 2024-09-30 | 35 K | Tocqueville Asset Management L.p. | 2024-09-30 | 32.8 K | Advisor Group Holdings, Inc. | 2024-06-30 | 25.4 K | Boothbay Fund Management, Llc | 2024-09-30 | 24.6 K | Xtx Topco Ltd | 2024-09-30 | 24 K | Two Sigma Investments Llc | 2024-09-30 | 22.9 K | Blackrock Inc | 2024-06-30 | 550.2 K | Altium Capital Management, Lp | 2024-09-30 | 545 K |
Tempest Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tempest Therapeutics Outstanding Bonds
Tempest Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tempest Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tempest bonds can be classified according to their maturity, which is the date when Tempest Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| TELUS P 37 Corp BondUS87971MBF95 | View | |
| TELUS P 46 Corp BondUS87971MBH51 | View | |
| TELUS P 28 Corp BondUS87971MBD48 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| TCN 34 13 MAY 32 Corp BondUS87971MBW29 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.